Tempest Therapeutics, Inc. — Form 8-K
Filed October 30, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Tempest Therapeutics filed an 8-K on 2026-10-30 reporting Item 5.02 (departure/appointment of officers and compensatory arrangements). The filing header indicates this relates to officer compensation but provides no concrete details: no names, dollar amounts, share counts, vesting schedules, or effective dates are disclosed in the accessible text. The actual compensation terms remain opaque from this submission.
Why this rating
Officer compensation routine disclosure absent specific material terms. At $30M market cap, even modest arrangements matter, but absence of quantified details precludes assessment of materiality.
Extracted items
See more from October 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.